Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Preleukemic Hematopoietic Stem Cells Identified in Acute Leukemia

By LabMedica International staff writers
Posted on 12 Mar 2014
A preleukemic stem cell has been discovered that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

AML is an aggressive blood cancer that starts in stem cells in the bone marrow. More...
A mutation in a gene causes preleukemic stem cells to develop that function like normal blood stem cells but grow abnormally. These cells survive chemotherapy and can be found in the bone marrow at remission, forming a reservoir of cells that may eventually acquire additional mutations, leading to relapse.

Scientists at the Princess Margaret Cancer Center (Toronto, ON, Canada) and their international collaborators carried out genomic analysis of more than 100 leukemia genes on many patient samples. Genomic DNA was subjected to limited whole-genome amplification (RepliG, Qiagen; Valencia, CA, USA) to obtain the required amount of input DNA for the SureSelect protocol (Agilent; Santa Clara, CA, USA).

Amplified genomic DNA was mechanically sheared using the M220 Focused-ultrasonicaton (Covaris; Woburn, MA, USA) and sequencing adaptors (Illumina; San Diego, CA, USA) were ligated to fragments to make a sequencing library. Droplet digital polymerase chain reaction (ddPCR) on genomic DNA and fluorescence-activated cell sorting of human stem/progenitor and mature cell populations were also carried out.

The investigators discovered that that in about 25% of AML patients, a mutation in the gene DNA (Cytosine-5-)-Methyltransferase 3 Alpha (DNMT3a) causes preleukemic stem cells to develop that function like normal blood stem cells but grow abnormally.

John Dick PhD, a professor and the senior author of the study said, “Now we have a potential tool for earlier diagnosis that may allow early intervention before the development of full AML. We can also monitor remission and initiate therapy to target the preleukemic stem cell to prevent relapse. Our study suggests that in some cases the chemotherapy does, in fact, eradicate AML; what it does not touch are the preleukemic stem cells that can trigger another round of AML development and ultimately disease relapse.”

The study was published on February 12, 2014, in the journal Nature.

Related Links:

Princess Margaret Cancer Center
Qiagen 
Covaris




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.